Pharmaceutical Supply – Guaifenesin Extended-Release Tablets

This contract involves the supply of FDA-compliant Guaifenesin Extended-Release Tablets with a dosage of 600 mg, packaged in bottles containing 500 tablets each. The agreement covers comprehensive requirements including proper labeling, adherence to shelf-life standards, and compliance with hazard communication regulations to ensure product safety and regulatory conformity. The procurement is designated as a subcontract under the Department of Defense's Medical Supply Chain Pharmaceutical FSA. The place of performance is specified as Fort Bragg, with the solicitation posted on May 18, 2026, and responses due by May 26, 2026. The contract falls under NAICS code 325412, which pertains to pharmaceutical manufacturing. While specific details such as the solicitation number and direct points of contact are not provided, the official opportunity is accessible via a Department of Defense electronic procurement platform. This contract reflects a critical procurement effort aimed at supporting medical supply chain needs with high-standard pharmaceutical products.